US OptionsDetailed Quotes
HUMA241220P17500
- 0.00
- 0.000.00%
15min DelayClose Nov 21 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover546.80%IV-299.54%PremiumDec 20, 2024Expiry Date13.12Intrinsic Value100Multiplier29DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5550Delta0.0595Gamma0.31Leverage Ratio-0.0452Theta-0.0091Rho-0.17Eff Leverage0.0049Vega
Humacyte Stock Discussion
Sign in to post a comment
$Humacyte (HUMA.US)$ shd i sell this shit stock ?
1
$Humacyte (HUMA.US)$ Humacyte Presents Preclinical Results Of Small-Diameter ATEV For Coronary Artery Bypass Grafting At American Heart Association's Scientific Sessions 2024; SdATEV Was Observed To Recellularize With Host Cells And Remodel To Effectively Reduce The Initial Size Mismatch Between The SdATEV And The Animal's Native Artery
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
2
$Humacyte (HUMA.US)$
what happened? the earnings suck but now the stock is rising
what happened? the earnings suck but now the stock is rising
1
$Humacyte (HUMA.US)$ Look at the price target from two days ago..$25..
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
1
5
unbelievable , looking at success rate and returns my success rate and return is little bit higher around above breakeven current year 
$Humacyte (HUMA.US)$
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Humacyte (HUMA) presented positive Phase 3 clinical trial results for their ATEV (acellular tissue engineered vessel) in arteriovenous access for hemodialysis patients. The trial demonstrated superior performance compared to standard autogenous fistula, with 81.3% functional patency at 6 months versus 66.4%, and 68.3% seco...
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Humacyte (HUMA) presented positive Phase 3 clinical trial results for their ATEV (acellular tissue engineered vessel) in arteriovenous access for hemodialysis patients. The trial demonstrated superior performance compared to standard autogenous fistula, with 81.3% functional patency at 6 months versus 66.4%, and 68.3% seco...
1
$Humacyte (HUMA.US)$ FDA Form 483 Highlights Key Compliance Issues at Humacyte Global, Including Microbial Testing Gaps, Delayed OOS Investigations, And Deficiencies in Quality Management; Aims To Address Safety And Quality Concerns Under Federal Food, Drug, And Cosmetic Act
2
3
$Humacyte (HUMA.US)$ finally it start moving up
$Humacyte (HUMA.US)$ What a heck was it? They did it agsin! only a moment of joy 😵💫
1
1
$Humacyte (HUMA.US)$ take profits to RR Richtech Robotics using a i Nvidia chip with a showing soon 🐂💥🚀📈
No comment yet
Flowerhill : I thought this company’s product is wonderful but I guess they cannot sell. I am stuck